Shares of Epizyme Inc. (NASDAQ:EPZM) traded down 4.6% on Tuesday . The company traded as low as $9.86 and last traded at $9.87, with a volume of 266,330 shares. The stock had previously closed at $10.35.

A number of analysts recently weighed in on the stock. Leerink Swann reaffirmed an “outperform” rating and issued a $39.00 price objective on shares of Epizyme in a research note on Tuesday, June 21st. Citigroup Inc. assumed coverage on shares of Epizyme in a research note on Tuesday, April 5th. They issued a “buy” rating and a $17.00 price objective for the company. Zacks Investment Research lowered shares of Epizyme from a “buy” rating to a “sell” rating in a research note on Tuesday, July 12th. JMP Securities reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Epizyme in a research note on Thursday, June 23rd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $22.00 price objective on shares of Epizyme in a research note on Monday, May 9th. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. Epizyme currently has an average rating of “Buy” and a consensus price target of $23.11.

The stock’s 50-day moving average is $10.33 and its 200-day moving average is $10.50. The company’s market cap is $564.78 million.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.12. Analysts forecast that Epizyme Inc. will post ($2.25) EPS for the current year.

In related news, insider Robert A. Copeland sold 4,000 shares of the firm’s stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $10.03, for a total transaction of $40,120.00. Following the completion of the sale, the insider now directly owns 4,000 shares of the company’s stock, valued at approximately $40,120. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Other hedge funds have modified their holdings of the company. Jennison Associates LLC increased its stake in shares of Epizyme by 252.4% in the fourth quarter. Jennison Associates LLC now owns 893,913 shares of the biopharmaceutical company’s stock worth $14,320,000 after buying an additional 640,245 shares during the last quarter. California Public Employees Retirement System purchased a new position in Epizyme during the fourth quarter valued at $2,723,000. Finally, Jennison Associates increased its position in Epizyme by 0.6% in the third quarter. Jennison Associates now owns 253,668 shares of the biopharmaceutical company’s stock valued at $3,262,000 after buying an additional 1,551 shares in the last quarter.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.